UnitedHealth Group vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Minnetonka US largest healthcare company (NYSE: UNH) at $400.3B 2024 revenue with UnitedHealthcare + Optum; 2025 leadership transition (Hemsley return, Witty departure) and suspended outlook after Change Healthcare breach and elevated medical costs.
About
UnitedHealth Group is a Minnetonka, Minnesota-based healthcare and insurance conglomerate — publicly traded on the New York Stock Exchange (NYSE: UNH) as the largest healthcare company in the United States by revenue — reporting $400.3 billion in 2024 revenues and operating through two complementary platforms: UnitedHealthcare (health insurance serving 50+ million people) and Optum (health services including OptumHealth care delivery, OptumRx pharmacy benefit management, and OptumInsight technology and analytics). Employing approximately 400,000 people globally across 500+ locations, UnitedHealth Group has been transformed by a turbulent 2024-2025 period: the Change Healthcare ransomware cyberattack (February 2024) disrupted healthcare payments for 190 million Americans; UnitedHealthcare CEO Brian Thompson was murdered in December 2024 in New York City; and CEO Andrew Witty resigned for personal reasons in May 2025, with founder-era CEO Stephen Hemsley returning to lead the company and the 2025 earnings outlook suspended amid higher-than-expected medical costs.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.